Sandoz launches filgrastim in UK
This article was originally published in Scrip
Executive Summary
Sandoz (Novartis) has launched its third biosimilar product in the UK, Zarzio (filgrastim), for the treatment of neutropenia associated with chemotherapy or advanced HIV infection. Amgen's Neupogen is the innovative reference product.